Osouli-Bostanabad Karim, Adibkia Khosro
Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
Students Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Bioimpacts. 2018;8(2):77-79. doi: 10.15171/bi.2018.09. Epub 2018 Mar 10.
Layer-by-layer fabrication of three dimensional (3D) objects from digital models is called 3D printing. This technology established just about three decades ago at the confluence of materials science, chemistry, robotics, and optics researches to ease the fabrication of UV-cured resin prototypes. The 3D technology was rapidly considered as a standard instrument in the aerospace, automotive, and consumer goods production factories. Nowadays, research interests in the 3D printed products have been raised and achieved ever-increasing traction in the pharmaceutical industry; so that, the first 3D printed drug product was approved by FDA in August 2015. This editorial summarizes the competitive advantages of the 3D printing for the made-on-demand, personalized and complex products, manufacturing of which establish opportunities for enhancing the accessibility, effectiveness, and safety of drugs.
从数字模型逐层制造三维（3D）物体的过程称为3D打印。这项技术大约在三十年前，在材料科学、化学、机器人技术和光学研究的交汇处应运而生，旨在简化紫外线固化树脂原型的制造。3D技术很快就在航空航天、汽车和消费品生产工厂中被视为一种标准工具。如今，3D打印产品的研究兴趣已经兴起，并在制药行业获得了越来越多的关注；因此，首款3D打印药品于2015年8月获得美国食品药品监督管理局（FDA）批准。这篇社论总结了3D打印在按需制造、个性化和复杂产品方面的竞争优势，这些产品的制造为提高药物的可及性、有效性和安全性创造了机会。
